Alerta

Fiber optic sensor for testing for SARS-CoV-2 and method of making the sensor

Resumen de: PL449093A1

Przedmiotem zgłoszenia jest czujnik światłowodowy do badań na obecność SARS-CoV-2 oraz sposób wykonania tego czujnika. Czujnik światłowodowy do badań na obecność SARS-CoV-2, oparty na rezonansowym efekcie (LMR) oraz sposób wykonania tego czujnika. Obszarze czujnikowym (3) o długości od 5 do 100 mm znajdującym się na odsłoniętym rdzeniu (2) lub na bocznie pocienionym włóknie z pozostawieniem płaszcza resztkowego o grubości do 5 µm lub też na bocznie pocienionym włóknie z całkowicie pocienionym bocznie płaszczem (1) i częściowo do 20% pocienionym bocznie rdzeniem ma powłokę dielektryczną (4) o grubości co najmniej 10 nm. Część rzeczywista współczynnika załamania powłoki ma wartość większą niż wartość współczynnika załamania rdzenia włókna światłowodowego, a część urojona współczynnika załamania ma wartość bliską zeru lecz niezerową. Powłoka dielektryczna pokryta jest warstwą funkcjonalizacji (5) wykonanej metodą silanizacji i posiada unieruchomione na niej receptory (6) analitów pochodzących od SARS-CoV-2, w postaci przeciwciał skierowanych przeciwko jednemu z białek strukturalnych SARS-CoV-2 czyli przeciwciał anti-S albo przeciwciał anti-E albo przeciwciał anti-M albo przeciwciał anti-N.

COMPOUNDS AS NLRP3 INHIBITORS, AND COMPOSITIONS AND USES THEREOF

Resumen de: WO2026006510A1

NOD-like receptor protein 3 (NLRP3) inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using the NSIs to inhibit inflammation and prevent or treat NRLP3 inflammasome dysregulation associated diseases and conditions, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID-19, diabetes, macular degeneration, and autoimmune/autoinflammatory diseases.

COMPOUNDS AS NLRP3 INHIBITORS AND COMPOSITIONS AND USES THEREOF

Resumen de: WO2026006505A1

NSIs with anti-inflammatory activity are provided, as are methods of using the NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID- 19, diabetes, macular degeneration, or an autoimmune or autoinflammatory disease.

COMPOUNDS AS NLRP3 PET RADIOTRACERS AND COMPOSITIONS AND USES THEREOF

Resumen de: WO2026006503A1

NLRP3 PET radiotracers are provided, as are methods of using the NLRP3 PET radiotracers to image and/or diagnose diseases and conditions associated with inflammation, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID- 19, diabetes, macular degeneration, and autoimmune/autoinflammatory diseases.

2-(PIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE ANALOGS AND USES THEREOF

Resumen de: WO2026006247A1

2-(Piperidin-3-yl)isoindole-1,3-dione analogs and uses thereof are disclosed. The compounds have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof. The compounds may be useful for inhibiting TNF-α activity, TNF-α synthesis, interleukin-6 (IL-6) level, inflammation, or SARS-COV-2 virus. In some aspects, the compounds, or pharmaceutical compositions including the compounds, are administered to a subject a traumatic brain injury (TBI), an inflammatory disorder, a neurodegenerative disease, cancer, a viral infection, or any combination thereof.

PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION

Resumen de: US20260000668A1

Provided herein are compositions comprising one or more diphenyl compounds, such as ANAVEX 1066, or its metabolites, or isomers, or salts, for use in treating symptoms of, or preventing an infection by a coronavirus, particularly an infection caused by a SARS-COV-2 virus.

ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE

Resumen de: US20260000752A1

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS

Resumen de: US20260000698A1

Disclosed herein are compounds of formulaor pharmaceutically acceptable salts thereof, and methods of using the same for treating a viral infection or inhibiting replication of a virus.

Medicated diet composition for treating heat cough, and preparation method therefor and use thereof

Resumen de: GB2642116A

A medicated diet composition for treating a heat cough, prepared from the raw materials in the following parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix and 5-10 parts of Platycodonis radix. The medicated diet composition can improve the symptoms of a heat cough of a SARS-CoV-2 infection.

COMPOSITION FOR PREVENTING OR TREATING CHEMOSENSORY DISORDER

Resumen de: EP4670725A1

The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, comprising a lactic acid bacterium. The chemosensory disorder can be a chemosensory disorder that occurs after SARS-CoV-2 viral infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect against a chemosensory disorder, and a pharmaceutical product or a food product that is safe for mammals including humans can be provided.

AN EPITOPE ORIGINATING FROM SARS-COV-2 N PROTEIN, AN ANTIGEN CONTAINING THE EPITOPE, USES THEREOF AND A METHOD FOR DETECTING DISEASE CAUSED BY CORONAVIRUS

Resumen de: WO2024177525A2

Epitopes originating from SARS-CoV-2 N protein, vaccine antigens specific for SARS-CoV-2 containing the epitopes useful in the treatment or prevention of disease caused by coronavirus as well as a method for detecting disease caused by coronavirus, in particular COVID-19, especially with an acute course, are disclosed.

SARS-COV-2 NEUTRALIZING ANTIBODIES

Resumen de: TW202440626A

The present invention relates to antibodies or antigen-binding fragments thereof against SARS- related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof, the pharmaceutical compositions and the kits for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus. The present invention further relates to methods of treating, preventing or reducing the severity of an infection with a SARS-related coronavirus, and to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

HUMANIZED MONOCLONAL ANTIBODY EFFICIENTLY NEUTRALIZING SARS-COV-2 VARIANT STRAIN AND USE THEREOF

Resumen de: WO2025260223A1

Specifically, the present invention relates to a humanized monoclonal antibody efficiently neutralizing a SARS-CoV-2 variant strain and a use thereof. Six CDR regions of the antibody are as shown in SEQ ID NOs: 1-6; a heavy chain variable region of the monoclonal antibody has a full length of an amino acid sequence as shown in SEQ ID NO: 7; and a light chain variable region of the monoclonal antibody has a full length of an amino acid sequence as shown in SEQ ID NO: 8. By using B-cell culture combined with antibody cloning technology and by means of a cross-reactive antibody screening strategy, a human monoclonal antibody 2F8 with efficient neutralization activity is obtained from a patient having recovered from original SARS-CoV-2 infection. The antibody can effectively resist neutralization escape by the SARS-CoV-2 variant strain and can be used for passive prevention in a population at a high risk of SARS-CoV-2 infection and the treatment of COVID-19.

PHARMACEUTICAL COMPOSITION FOR PASSIVE IMMUNIZATION OR THERAPY

Resumen de: WO2025262025A1

The present invention pertains to pharmaceutical compositions comprising protein oligomers for passive immunization and therapy. Specifically, the present invention relates to a pharmaceutical composition comprising a protein oligomer comprising at least a first and a second monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first receptor binding domain (RBD), an immunoglobulin Fc (Ig Fc), and at least one second receptor binding domain (RBD), wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13.

EFFICIENT VACCINE

Resumen de: WO2025263616A1

Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprises CD8+ T cell epitope. Provided herein is also a bivalent alphavirus replicon vaccine, which is a combination of a first polynucleotide which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and an antigenic peptide and a second polynucleotide which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a CD8+ T cell epitope. The vaccine is useful against virus infection, especially, COVID-19 or SARS-CoV-2 infection, the treatment of a cancer and/or an inflammatory disease.

SIMULTANEOUS DETECTION OF PROTEINS AND NUCLEIC ACIDS USING PROXIMITY LIGATION OF APTAMERS AND QUANTITATIVE POLYMERASE CHAIN REACTION

Resumen de: WO2025262670A1

A method and composition for the simultaneous detection of a protein and a nucleic acid within a single biological sample using proximity ligation of aptamers and quantitative polymerase chain reaction (qPCR) is disclosed. The invention employs two aptamers, each targeting a distinct epitope of the protein of interest, functionalized with primer sites to enable ligation by way of a short DNA linker in the presence of the protein. This ligated construct is then amplified and detected using qPCR. Concurrently, viral RNA is detected in the same reaction using reverse transcription- qPCR (RT-qPCR) with TaqMan probes in a separate fluorescent channel. This dual detection approach is demonstrated with SARS-CoV-2 nucleocapsid protein and RNA and is validated in saliva samples and digital droplet PCR. The invention provides a sensitive, rapid, and specific method for multiplexed molecular diagnostics.

PROTEIN OLIGOMERS FOR ACTIVE IMMUNIZATION

Resumen de: WO2025262023A1

The present invention pertains to protein oligomers for active immunization. Specifically, the invention relates to protein oligomers comprising at least a first monomer and a second 5 monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first RBD, an immunoglobulin Fc (Ig Fc), and at least one second RBD, wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or a fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13. The invention further relates to a vaccine comprising said protein oligomer, preferably for use in active immunization and/or booster vaccination in a subject.

Method and System for Exposing Hidden or Masked Antigenic Sites of Viral Specimens Present in Biosamples Using a Home-Based COVID-19 Rapid Lateral Flow Immunoassay Test

Resumen de: US2025389719A1

A disease detection system including a platform or cartridge to perform testing using a rapid lateral flow chromatographic immunoassay (LFIA) test intended for the qualitative detection of the disease in a sample, such as collected sputum, disrupted by a digestive enzyme and a detergent to release its content and digest its proteins and other polymeric molecules. A method of the present invention includes treating a sample with a digestive enzyme and a detergent to disrupt the collected sample releasing content and digesting proteins of the sample to form a lysed-digested-extracted sample, applying the lysed-digested-extracted sample to a platform or cartridge, performing a rapid lateral flow chromatographic immunoassay (LFIA) test of the lysed-digested-extracted sample using the platform or cartridge and detecting presence or absence of an analyte of interest from the tested lysed-digested-extracted sample.

SARS-COV-2 LACKING THE ENVELOPE PROTEIN AS AN ATTENUATED VACCINE VIRUS AGAINST COVID-19

Resumen de: US2025387467A1

An isolated nucleic acid comprising a recombinant coronavirus genome having a genetic modification that inhibits or prevents expression of coronavirus envelope (E) protein and/or M protein, a vaccine comprising the recombinant genome and methods of using the vaccine are provided.

Methods and Compositions for Treating Infections

Resumen de: US2025387468A1

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.

Nutraceutical Composition for Multimodal Prophylaxis

Resumen de: US2025387429A1

A phytochemical and nutraceutical composition and method for protection against a wide spectrum of viral and bacterial infections, including Covid-19, and for treatment of established infection and infectious inflammation. The composition includes a novel combination of vitamin, mineral, nutraceutical and phytochemical supplements. The composition of supplements and method may be compounded as a pill, tablet, powder, capsule or liquid be taken orally one or more times per day, and parenteral including nasal sprays and inhalers. Vitamin C and vitamin E along with zinc complexed with pyrithione or citrate are used in conjunction with nutraceuticals and phytochemicals provided, respectively, as immune boosters and antiviral agents along with anti-inflammatory nutraceuticals and phytochemicals.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EPIDEMIC RNA VIRAL INFECTIOUS DISEASE

Resumen de: UA130231C2

The present invention relates to a use of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof for preventing or treating an epidemic RNA viral infectious disease, and more specifically, to a pharmaceutical composition for preventing or treating an epidemic RNA viral infectious disease, in particular, Coronavirus Disease 2019 (COVID-19), the composition comprising a therapeutically effective amount of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.

METHOD FOR OBTAINING 3-(41-CHLOROBENZYL)-MERCAPTO-6-(4-R-BENZYL)-4H-1,2,4-TRIAZINE-5-ONES WITH PREDICTED ACTIVITY AGAINST SARS-COV-2 VIRUS

Resumen de: UA161684U

Method for obtaining 3-(41-chlorobenzyl)-mercapto-6-(4-R-benzyl)-4H-1,2,4-triazine-5-ones with predicted activity against SARS-CoV-2 virus, in which equimolar amounts of 3-mercapto-6 -(4-R-benzyl)-4H-1,2,4-triazine-5-ones and 4-chlorobenzyl chloride are boiled in dry acetonitrile with stirring in the presence of calcined K2CO3 for three hours, after which the reaction mass is cooled, poured into ice water, the precipitate is filtered, dried, and crystallized from propanol-2.

METHOD FOR OBTAINING 6-BENZYL-3-ARYLAMINO-4H-1,2,4-TRIAZINE-5-ONES WITH PREDICTED ACTIVITY AGAINST THE SARS-COV-2 VIRUS

Resumen de: UA161685U

Method for obtaining 6-benzyl-3-arylamino-4H-1,2,4-triazine-5-ones with predicted activity against the SARS-CoV-2 virus: where R=OCHF2, NHC6H5, whereby equimolar amounts of 6-benzyl-3-methylsulfanil-4H-1,2,4-triazine-5-one and the corresponding substituted aromatic amine are heated in an oil bath at a temperature of 170 °C for two hours in an argon atmosphere; after cooling, the reaction mixture is ground with propanol-2, the crystalline precipitate is filtered off, washed with propanol-2, dried, and purified by crystallization from ethanol.

PRODUCTION METHOD

Nº publicación: AU2024266327A1 18/12/2025

Solicitante:

AG IP COMPANY PTY LTD
AG IP COMPANY PTY LTD

Resumen de: AU2024266327A1

The invention relates, inter alia, to methods of preparing a garlic oil, garlic oils produced using the method, pharmaceutical compositions comprising the garlic oil and uses of the garlic oil in the treatment of viral infections such as SARS-COV-2 and influenza A. The methods of preparing a garlic oil comprise the steps of: a) processing a portion of a garlic plant to increase its surface area; b) ageing the portion of the garlic plant for at least 18 months to provide an aged garlic, which does not comprise addition of ethanol; and c) separating the garlic oil in the aged garlic. Step c) may be performed using spinning cone distillation or supercritical fluid extraction, at a temperature below 110 °C, or such that the pressure (atmospheres) divided by the temperature (degrees Kelvin) is equal to or less than about 0.0026.